SynthesisFrontiers in neurology2026
Flash VEP-P2 latency delay in Alzheimer's disease and cognitive impairment: a systematic review and meta-analysis.
Synthesis in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The flash visual evoked potential P2 component (FVEP-P2) has been investigated as a potential neurophysiological measure of cognitive impairment, but its biological and clinical significance remains uncertain. However, evidence remains fragmented. This systematic review and meta-analysis aimed to quantitatively synthesize evidence on FVEP-P2 latency alterations across the cognitive impairment continuum, including mild cognitive impairment (MCI) and major neurocognitive disorders (dementia). Methods: We systematically searched PubMed, Embase, Web of Science, and Cochrane Library until July 28, 2025. Standardized mean differences (SMDs) for FVEP-P2 latency were pooled from 21 studies ( Results: Twenty-one studies involving 1,778 participants were included. FVEP-P2 latency was significantly prolonged in patients with AD compared with healthy controls (18 comparisons, SMD = 1.55, 95% CI 1.05-2.05, I Conclusion: Prolonged FVEP-P2 latency was observed in AD, with preliminary findings suggesting similar alterations in other forms or stages of cognitive impairment. These findings do not establish a specific neurobiological mechanism or diagnostic role. Further studies are needed to clarify the biological basis and clinical value of FVEP-P2 latency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.